ArticleRheumatology and therapy2022

Reasons for Initiating Canakinumab among Patients with Systemic Juvenile Idiopathic Arthritis and Adult-Onset Still's Disease in the U.S. Real-World Settings.

Peter Hur et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.